TVTX Stock Analysis: Travere Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.293m USD | 12M Return: 296.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 120M
Qual. Beats: 0
Rev. Trend: 93.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Travere Therapeutics (NASDAQ: TVTX) is a U.S.-based biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing, and commercializing therapies for rare kidney and metabolic diseases. The company was formerly known as Retrophin, Inc. before rebranding in November 2020.
Its marketed products include FILSPARI (sparsentan), a once-daily oral therapy that targets two pathways (endothelin 1 and angiotensin-II) in IgA Nephropathy progression, and Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurrent kidney stones.
Traveres clinical-stage pipeline includes sparsentan, which holds Orphan Drug Designation in both the U.S. and Europe for focal segmental glomerulosclerosis (FSGS), and Pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria. The company also maintains a collaboration with PharmaKrysto Limited for pre-clinical work on its cystinuria program.
As a mid-cap biotechnology company in the rare disease space, Travere operates within a sector that often benefits from regulatory incentives such as FDA Orphan Drug Designation, which typically grants several years of market exclusivity for therapies addressing conditions affecting small patient populations.
- FILSPARI commercial uptake drives revenue growth in IgA Nephropathy
- FSGS regulatory decision for sparsentan supplemental NDA remains key catalyst
- Cash burn widens as commercial launch spend and pipeline investment accelerate
| Net Income: -21.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 39.63 > 1.0 |
| NWC/Revenue: 49.84% < 20% (prev 70.09%; Δ -20.25% < -1%) |
| CFO/TA 0.07 > 3% & CFO 39.6m > Net Income -21.4m |
| Net Debt (78.6m) to EBITDA (38.5m): 2.04 < 3 |
| Current Ratio: 3.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (91.9m) vs 12m ago 3.98% < -2% |
| Gross Margin: 93.95% > 18% (prev 92.23%; Δ 1.73% > 0.5%) |
| Asset Turnover: 97.14% > 50% (prev 49.84%; Δ 47.30% > 0%) |
| Interest Coverage Ratio: -3.40 > 6 (EBIT TTM -34.6m / Interest Expense TTM 10.2m) |
| A: 0.48 (Total Current Assets 392.7m - Total Current Liabilities 125.4m) / Total Assets 555.2m |
| B: -2.72 (Retained Earnings -1.51b / Total Assets 555.2m) |
| C: -0.06 (EBIT TTM -34.6m / Avg Total Assets 552.0m) |
| D: 0.22 (Book Value of Equity 98.7m / Total Liabilities 456.5m) |
| Altman-Z'' = -5.90 = D |
| DSRI: 1.30 (Receivables 87.3m/34.4m, Revenue 536.2m/273.5m) |
| GMI: 0.98 (GM 92.23% / 93.95%) |
| AQI: 0.94 (AQ_t 0.27 / AQ_t-1 0.29) |
| SGI: 1.96 (Revenue 536.2m / 273.5m) |
| TATA: -0.11 (NI -21.4m - CFO 39.6m) / TA 555.2m) |
| Beneish M = -2.16 (Cap -4..+1) = BB |
As of July 08, 2026, the stock is trading at USD 57.85 with a total of 1,273,325 shares traded. Over the past week, the price has changed by -0.77%, over one month by +22.88%, over three months by +82.66% and over the past year by +296.10%.
Current recommended Stop Loss: 55.20 (which is 4.6% or 1.2 ATR below the current price).
Travere Therapeutics has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy TVTX.
- StrongBuy: 11
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 58.4 | 0.9% |
P/E Forward = 76.9231
P/S = 9.8717
P/B = 53.0672
Revenue TTM = 536.2m USD
EBIT TTM = -34.6m USD
EBITDA TTM = 38.5m USD
Long Term Debt = 312.1m USD (from longTermDebt, last quarter)
Short Term Debt = 6.02m USD (from shortTermDebt, last quarter)
Debt = 343.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 15.6m
Net Debt = 78.6m USD (calculated: Debt 343.2m - CCE 264.7m)
Enterprise Value = 5.37b USD (5.29b + Debt 343.2m - CCE 264.7m)
Interest Coverage Ratio = -3.40 (Ebit TTM -34.6m / Interest Expense TTM 10.2m)
EV/FCF = 150.8x (Enterprise Value 5.37b / FCF TTM 35.6m)
FCF Yield = 0.66% (FCF TTM 35.6m / Enterprise Value 5.37b)
FCF Margin = 6.64% (FCF TTM 35.6m / Revenue TTM 536.2m)
Net Margin = -4.00% (Net Income TTM -21.4m / Revenue TTM 536.2m)
Gross Margin = 93.95% ((Revenue TTM 536.2m - Cost of Revenue TTM 32.4m) / Revenue TTM)
Gross Margin QoQ = 78.96% (prev none%)
Tobins Q-Ratio = 9.68 (Enterprise Value 5.37b / Total Assets 555.2m)
Interest Expense / Debt = 2.97% (Interest Expense 10.2m / Debt 343.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -27.3m (EBIT -34.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.84 (Total Current Assets 392.7m / Total Current Liabilities 138.3m)
Debt / Equity = 3.48 (Debt 343.2m / totalStockholderEquity, last quarter 98.7m)
Debt / EBITDA = 2.04 (Net Debt 78.6m / EBITDA 38.5m)
Debt / FCF = 2.21 (Net Debt 78.6m / FCF TTM 35.6m)
Total Stockholder Equity = 80.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.88% (Net Income -21.4m / Total Assets 555.2m)
RoE = -26.79% (Net Income TTM -21.4m / Total Stockholder Equity 80.0m)
RoCE = -8.83% (EBIT -34.6m / Capital Employed (Equity 80.0m + L.T.Debt 312.1m))
RoIC = -6.69% (negative operating profit) (NOPAT -27.3m / Invested Capital 409.0m)
WACC = 12.19% (E(5.29b)/V(5.64b) * Re(12.83%) + D(343.2m)/V(5.64b) * Rd(2.97%) * (1-Tc(0.21)))
Discount Rate = 12.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 8.49%
[DCF] Terminal Value 63.22% ; FCFF base≈35.6m ; Y1≈35.8m ; Y5≈37.9m
[DCF] Fair Price = 2.99 (EV 356.6m - Net Debt 78.6m = Equity 278.0m / Shares 93.0m; r=12.19% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.25 | # QB: 0
Revenue Correlation: 93.41 | Revenue CAGR: 58.95% | SUE: -0.43 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.33 | Chg30d=-8.57% | Revisions=+12% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.40 | Chg30d=-27.93% | Revisions=+38% | Analysts=8
EPS current Year (2026-12-31): EPS=1.87 | Chg30d=+4.33% | Revisions=+55% | GrowthEPS=+105.3% | GrowthRev=+42.2%
EPS next Year (2027-12-31): EPS=4.85 | Chg30d=-3.11% | Revisions=+0% | GrowthEPS=+159.6% | GrowthRev=+38.9%
[Analyst] Revisions Ratio: +34% (up=18, down=8)